{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-098809","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.937969+00:00","generated_at":"2026-06-10T22:54:23.831008+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Aziyo Biologics rebrands as Elutia; shifts to drug-eluting biomatrices; ticker now ELUT","bullets":["Name change to Elutia Inc. effective Sept 6, 2023; ticker switches from AZYO to ELUT on Nasdaq on Sept 7.","Rebranding reflects strategic focus on drug-eluting biomatrix (DEB) technology to improve surgical outcomes.","First DEB product CanGaroo RM for pacemaker/defibrillator market expected to launch next year; market valued at $600M.","Developing SimpliDerm RM for breast reconstruction ($500M market) to address post-op infection rates exceeding 10%.","CEO Randy Mills highlights commitment to DEB technology; no immediate financial impact or guidance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-098809","json":"https://secwatch.observer/filing/0001104659-23-098809.json","markdown":"https://secwatch.observer/filing/0001104659-23-098809.md","text":"https://secwatch.observer/filing/0001104659-23-098809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923098809/0001104659-23-098809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923098809/tm2325574d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:54:23.831008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c141e5912f1eaa4132a006e1c040aa53e70e8ed5","claim":"ELUTIA INC.: Company changed its corporate name from Aziyo Biologics, Inc. to Elutia Inc. by an amendment to its restated certificate of incorporation (effective 2023-09-06).","evidence_excerpt":"On September 6, 2023, Aziyo Biologics, Inc. (the “Company”) changed its corporate name to Elutia Inc., by an amendment to its restated certificate of incorporation filed with the Delaware Secretary of State (the “Name Change”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923098809/0001104659-23-098809-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"governance_change"},{"claim_id":"e494ba8bd2d06d8d2f8902935ed15658f3385cc4","claim":"ELUTIA INC.: Company amended and restated its bylaws to reflect the name change to Elutia Inc (effective 2023-09-06).","evidence_excerpt":"The Company also amended and restated its bylaws to reflect the Name Change.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923098809/0001104659-23-098809-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}